Abstract
Cardiotoxicity continues to be a major health issue worldwide due to the imperative need to access new or repurposed drugs that are safe and effective. Accessibility to affordable drugs is also key to ensure access to drugs to all patients who require them. In this work we propose a workflow for an in-silico clinical trial at the 3D biventricular human population level, to assess cardiac pro-arrhythmic risk after administration of a single or a combination of potentially cardiotoxic drugs.
The proposed workflow aims at reproducing gender-specific ionic channel characteristics that determine different responses of patients to drug-induced arrhythmia. To that end a “normal” virtual population of human 3D hearts at rest and exercise/stress (increased heart rate) was analyzed under the influence of drugs, using computer electrophysiology simulations. The changes in ECG, calcium concentration as well as activation patterns on 3D geometry were evaluated for the signs of arrhythmia. Hydroxychloroquine and Azithromycin were used to demonstrate the workflow. Additionally a series of experiments on a reanimated swine heart utilizing Visible Heart® methodologies were performed to verify the arrhythmic behaviour observed in the in-silico trial.
Our results showed similar results to the recently published clinical trials (21% clinical risk vs 21.8% in-silico trial risk). Evidence of transmurally heterogeneous action potential prolongation after a large dose of hydroxychloroquine was an observed mechanism of arrhythmia, both in the in-vitro and the in-silico model. The proposed workflow for the in-silico clinical drug cardiotoxicity trials allows reproducing the complex behavior of cardiac electrophysiology in a population and verifying drug-induced arrhythmic risk in a matter of a few days as compared to the in-vivo trials. Importantly, our results provided evidence of the normal phenotype variants that produce distinct drug-induced arrhythmogenic outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has received funding from the European Union Horizon 2020 research and innovation programme under grant agreements No 823712 (CompBioMed project, phase 2) and No 777204 (SilicoFCM project). Computation time was provided by PRACE-COVID-19 fast track pandemic response (project COVID1933) at the Joliot-Curie Rome supercomputer, hosted by GENCI at CEA, France. JA-S is funded by a Ramon y Cajal fellowship (RYC-2017-22532), MINECO, Spain. CB is funded by the Torres Quevedo Program (PTQ2018-010290), MINECO, Spain.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Minnesota Institutional Review Board and LifeSource Research Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
More details about the methodology and results were added.
Data Availability
Human cardiac database is hosted at the Visible Heart Laboratory, University of Minnesota website. Computational model results will become available after peer review publication.
